[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"congenital-myopathies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:congenital-myopathies":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639648","virtualparkpediatric-100639648",false,"NCT07580365","VirtualPark_Pediatric","Evaluation of the Impact of a Rehabilitation Intervention Based on Cycling With Virtual Park on Slowing the Functional Motor Decline of Neuromuscular Patients in Developmental Age","Inclusion Criteria:\n\n* availability of a definitive clinical or molecular genetic diagnosis of a neuromuscular disease;\n* age between 6 years and 17 years and 11 months (inclusive);\n* height compatible with the use of the Thera-Trainer (minimum 120 cm);\n* performance Upper Limb Module 2.0 assessment: Entry level \\>= 2\n\nExclusion Criteria:\n\n* other concomitant genetic diseases;\n* presence of visual impairments that prevent access to the experimental virtual reality protocol;\n* concomitant compromised cardio-respiratory function that contraindicates cycle ergometer training;\n* severe osteoporosis.","ALL","6 Years","18 Years",{"count":20,"type":21},22,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to assess the effects of a dual-task, multimodal training program on slowing functional motor decline in children and adolescents with neuromuscular disorders. The main questions it aims to answer are:\n\nDoes Virtual Park slow functional motor decline in children and adolescents with neuromuscular diseases compared with standard therapy?\n\nDoes Virtual Park contribute to increased engagement and improved neuropsychological function?\n\nIf there is a comparison group, Researchers will compare dual-task cycling supported by the Virtual Park application to standard therapy to see whether it improves motor and neuropsychological functions and engagement.\n\nParticipants will undergo two phases:\n\n* Phase 1: 3 months of standard therapy;\n* Phase 2: 3 months of experimental conditions in which patients undergo a rehabilitative intervention with Virtual Park, 3 times a week.",[27,28,29],"Dystrophinopathy","Muscular Dystrophies","Congenital Myopathies",[31,32,33,34,35,36],"Sports for Persons with Disabilities","Rehabilitation","Neuromuscular Diseases","Dual-Task Exercises","Virtual Reality","Children with Disabilities","NOT_YET_RECRUITING","2026-05-05",{"date":40,"type":41},"2026-05-12","ACTUAL",{"date":43,"type":21},"2026-06",{"date":45,"type":21},"2028-06",{"name":47,"class":48},"Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato","OTHER",4,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100624915","evaluation-of-the-role-of-mir-1-in-the-pathogenesis-and-as-a-biomarker-in-muscular-dystrophies-and-congenital-myopathies-100624915","NCT07415837","Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies","Dystro-miR1","Inclusion Criteria:\n\n* Age: Participants must be older than 2 years of age\n* Consent: Participants (or their legal guardians) must provide free and informed consent,. For children, the consent is oral for those under 6 years old and written for those over 6,.\n* Social Security: Every participant must be affiliated with the French social security system.\n* Participants must have a diagnosed neuromuscular pathology : the eligible pathologies are Myotonic Dystrophy Type 1 (DM1 or Steinert's disease), Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (DMB), or congenital myopathies or are healthy participants.\n\nExclusion Criteria:\n\n* Refusal to participate expressed by the subject or their parental authority.\n* Engaging in intense and unusual physical effort within 10 days before the blood draw.\n* Current use of any treatment with systemic, muscular, or cardiac effects that could interfere with the study's biological results.\n* Subjects or their legal guardians who are under tutelage, curatorship, deprived of liberty, or under judicial protection.\n* Women who are pregnant or breastfeeding.\n* The presence of an additional pathology that, in the judgment of the clinician, could interfere with the biological findings",true,"2 Years",{"count":60,"type":21},104,[24],"The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.\n\nMicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease.\n\nThe main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities:\n\n1. Patients with Duchenne or Becker muscular dystrophy (DMD\u002FDMB).\n2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease).\n3. Patients with congenital myopathies.\n4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.",[64,65,29,66],"Duchenne \u002F Becker Muscular Dystrophy","Dystrophia Myotonica 1","Healthy Participants",[68,69,70],"biomarkers","neuromuscular diseases","micro-RNAs","RECRUITING","2026-02-24",{"date":74,"type":41},"2026-02-25",{"date":76,"type":41},"2026-02-11",{"date":78,"type":21},"2029-03",{"name":80,"class":48},"University Hospital, Clermont-Ferrand",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":57,"sex":16,"minAge":88,"maxAge":18,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":81},"100603626","phenotype---genotype-correlation-in-a-sample-of-egyptian-patients-with-congenital-myopathies-and-congenital-muscular-dystrophies-100603626","NCT07138963","Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies","Inclusion Criteria:\n\n* Patients with clinical criteria of Congenital Myopathies (CMs) and Congenital Muscular dystrophies (CMDs) with different modes of inheritance.\n* Age: patients below age of 18 years.\n* Gender: Both males and females are included\n* Genetically confirmed CMs and CMDs.\n\nExclusion Criteria:\n\n* Patients above 18 years.\n* Spinal muscular atrophy (SMA),and root lesions.\n* Congenital myasthenic syndromes\n* Dystrophinopathies,Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy (LGMD)\n* .Metabolic myopathies\n* .Inflammatory muscle diseases","1 Year",{"count":90,"type":21},25,"OBSERVATIONAL","The aim of this study is to correlate the phenotype and genotype among a sample of Egyptian patients with Congenital myopathies and Congenital muscular dystrophies.",[94,95,96,97,98,29,99],"Phenotype","Genotype","Correction","Sample","Egyptian Patients","Congenital Muscular Dystrophies","2025-08-17",{"date":102,"type":41},"2025-08-24",{"date":104,"type":41},"2024-06-30",{"date":106,"type":21},"2026-06-30",{"name":108,"class":48},"Ain Shams University"]